Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts

Executive Summary

The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.

You may also be interested in...



Seagen/Genmab's Tivdak Set To Take On Merck’s Keytruda

Accelerated approval of Tivdak in recurrent or metastatic cervical cancer brings Seagen’s fourth cancer therapy and third antibody-drug conjugate to market. Merck is advancing Keytruda in r/mCC as well.

Lilly Tops Biopharma Innovation Survey For First Time

Conducting sector survey for a tenth year, Idea Pharma’s Mike Rea said: “COVID-19 showed companies with more agile decision-making were more likely to succeed.”

Twice As Nice: Seattle Genetics, Merck & Co. Partner On Two Cancer Drugs

Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel